Table 1.

Patient characteristics and genetic types of WHO II-IV gliomas

Characteristics	LGGs		HGGs	Total	P value
	WHO II n = 36 (32.43%)	WHO III n = 32 (28.83%)	WHO IV n = 43 (38.74%)	WHO II-IV n = 111 (100.00%)	LGGs vs HGGs
Age	42.4 $\pm 11.6$	46.5 $\pm 12.4$	57.8 $\pm 15.0$	44.3 $\pm 12.1$	P < 0.0001
Sex					P = 0.035
Male	24 (66.67%)	19 (59.38%)	15 (34.88%)	58 (52.25%)
Female	12 (33.33%)	13 (40.62%)	28 (65.12%)	53 (47.75%)
Genetic type
IDH					P < 0.0001
Mutation	27 (75.00%)	15 (46.88%)	3 (6.98%)	45 (40.54%)
Wildtype	9 (25.00%)	17 (53.12%)	39 (90.70%)	65 (58.56%)
NA	0 (0.00%)	0 (0.00%)	1 (2.32%)	1 (0.90%)
MGMT					P = 0.002
Methylated	28 (77.78%)	21 (65.63%)	17 (39.53%)	66 (59.46%)
Unmethylated	6 (16.67%)	10 (31.25%)	26 (60.47%)	42 (37.84%)
NA	2 (5.55%)	1 (3.12%)	0 (0.00%)	3 (2.70%)
TERT					P = 0.471
Mutation	17 (47.22%)	13 (40.62%)	25 (58.14%)	55 (49.55%)
Wildtype	17 (47.22%)	15 (46.88%)	13 (30.23%)	45 (40.54%)
NA	2 (5.56%)	4 (12.50%)	5 (11.63%)	11 (9.91%)

Unless otherwise noted, data in the table are presented as n (%) or mean $\pm$ standard deviation; NA: not available

LGGs low grade gliomas; HGGs high grade gliomas